epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLCepilepsia-102Research ArticleCLINICAL LECTURESКЛИНИЧЕСКИЕ ЛЕКЦИИУПРАВЛЕНИЕ НЕЖЕЛАТЕЛЬНЫМИ ЯВЛЕНИЯМИ, ВОЗНИКАЮЩИМИ НА ФОНЕ ПРИЕМА ПЕРАМПАНЕЛАЖидковаИ. А.

Жидкова Ирина Александровна - доктор медицинских наук, профессор кафедры нервных болезней лечебного факультета МГМСУ имени А.И. Евдокимова; невролог-эпилептолог медицинского центра «Невромед-клиника», Член Российской Противоэпилептической Лиги

Московский государственный медико-стоматологический университет имени А. И. Евдокимова, Москва; Невромед-клиника, МоскваRussian Federation20140606201665Special issue1315Copyright © Жидкова И.А., 20162016Жидкова И.А.Жидкова И.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/102

.

ReferencesFrench J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.French J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3- hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onsetseizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126-34.Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3- hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onsetseizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126-34.Rektor I. et al. Perampanel Study 207: long term open label evaluation in patients with epilepsy. Acta Neurol Scand 2012; 126: 263-9.Rektor I. et al. Perampanel Study 207: long term open label evaluation in patients with epilepsy. Acta Neurol Scand 2012; 126: 263-9.Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.Franco V. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013; 70: 35-40.Franco V. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013; 70: 35-40.Davies S., Heyman I., Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003; 45: 292-5.Davies S., Heyman I., Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003; 45: 292-5.Инструкция по медицинскому применению прапарата Файкомпа РУ ЛП 002200 от 23.08.2013.Инструкция по медицинскому применению прапарата Файкомпа РУ ЛП 002200 от 23.08.2013.

The authors declare that there are no conflicts of interest present.